EMA has granted Orphan Drug Designation to ONCO-Boost (HEPHAISTOS-Pharma) as treatment for osteosarcoma

6 septembre 2022

Paris, France, September 1st, 2022, 7:00 pm CET.

HEPHAISTOS-Pharma a French Biotech company developing a new class of immunotherapies to address hard-to-treat and metastatic cancers, today announced that the European Commission granted Orphan Drug designation (ODD) to ONCO-Boost for the treatment of osteosarcoma.

“This designation is an important milestone in the development of ONCO-Boost and demonstrate its potential clinical benefits for sarcoma patients who have an urgent need for effective, tolerable, and convenient treatment options” said Frédéric Caroff, CEO and co-founder of HEPHAISTOS-Pharma. “This key milestone was reached thanks to the collaboration of HEPHAISTOS-Pharma with the academic teams from Pr. Charles Dumontet at the Centre de Recherche contre le Cancer de Lyon (CRCL), and Pr. Jean-Yves Blay at the Centre Léon Bérard (CLB). These collaborations have demonstrated the potential clinical benefit of ONCO-Boost against sarcomas such as osteosarcoma and chondrosarcoma, but also against Lymphoma, colorectal and breast cancers. The company is now heading toward regulatory validation and expects a first clinical study by 2023.”

To know more